Sign in or create an account to add this stock to your watchlist.
About Shire Viropharma (NASDAQ:VPHM)
ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions
What is Shire Viropharma's stock symbol?
Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."
How were Shire Viropharma's earnings last quarter?
Shire Viropharma Inc (NASDAQ:VPHM) released its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.15. The biotechnology company earned $113 million during the quarter, compared to the consensus estimate of $113.35 million. The business's revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. View Shire Viropharma's Earnings History.
Has Shire Viropharma been receiving favorable news coverage?
News headlines about VPHM stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Shire Viropharma earned a daily sentiment score of 0.17 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Shire Viropharma?
Shares of VPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Shire Viropharma?
Shire Viropharma has a market capitalization of $3.30 billion.
How can I contact Shire Viropharma?
Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.
MarketBeat Community Rating for Shire Viropharma (VPHM)MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe VPHM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VPHM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire Viropharma (NASDAQ:VPHM) Analyst Ratings History
(Data available from 5/24/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Shire Viropharma (NASDAQ:VPHM) Earnings History and Estimates Chart
Shire Viropharma (NASDAQ VPHM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/24/2013||Q313||$0.05||$0.20||$113.35 million||$113.00 million||View||N/A|
|8/1/2013||Q2 2013||$0.01||$0.15||$105.06 million||$104.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.04||$0.15||$108.47 million||$107.00 million||View||N/A|
|2/27/2013||Q4 2012||$0.03||$0.10||$103.06 million||$106.50 million||View||N/A|
Shire Viropharma (NASDAQ:VPHM) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Shire Viropharma (NASDAQ VPHM) News Headlines
Shire Viropharma (NASDAQ:VPHM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Shire Viropharma (NASDAQ:VPHM) Income Statement, Balance Sheet and Cash Flow Statement
Shire Viropharma (NASDAQ VPHM) Stock Chart for Thursday, May, 24, 2018